Literature DB >> 21556292

Sources of heterogeneity in hepatitis B virus (HBV) seroprevalence estimates from U.S. adult incarcerated populations: A systematic review and meta-regression analysis.

Amy J Harzke1, Karen J Goodman, Patricia D Mullen, Jacques Baillargeon.   

Abstract

HBV seroprevalence estimates from U.S. incarcerated populations are relatively high. However, the usefulness of these estimates for guiding HBV-related correctional healthcare policy is limited by wide variation in estimates across studies and little understanding of the sources of this variation. The authors systematically reviewed studies indexed from 1975-2005, meeting pre-specified criteria and reporting HBV seroprevalence estimates from U.S. adult incarcerated populations. Using meta-regression techniques, the authors investigated report type, geographical region, serum collection year, facility type, serum source, sampling procedures, sample characteristics, and measurement procedures as potential study-level sources of heterogeneity in prevalence estimates for common HBV seromarkers. In bivariable meta-regression analyses, mean age ≥31 years was strongly associated with increased HBsAg prevalence (POR=2.6), and serum collection year before 1991 was strongly associated with increased prevalence of any positive marker (POR=2.0). Other moderate-to-strong associations were observed, but these were considered less certain because of small numbers of observations, influence of single studies, or potential confounding. Potential sources of heterogeneity should be considered when comparing HBV seroprevalence estimates in adult U.S. incarcerated populations and when developing HBV screening and vaccination protocols in correctional settings.

Entities:  

Year:  2010        PMID: 21556292      PMCID: PMC3089417     

Source DB:  PubMed          Journal:  Int J Prison Health        ISSN: 1744-9200


  31 in total

1.  Aging prisoners stressing health care system.

Authors:  Mike Mitka
Journal:  JAMA       Date:  2004-07-28       Impact factor: 56.272

2.  Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons.

Authors:  Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

3.  Community incidence of hepatitis B and C among reincarcerated women.

Authors:  Grace E Macalino; David Vlahov; Brian P Dickinson; Beth Schwartzapfel; Josiah D Rich
Journal:  Clin Infect Dis       Date:  2005-08-30       Impact factor: 9.079

4.  Hepatitis B carriers in the prison population.

Authors:  T Bader
Journal:  N Engl J Med       Date:  1983-02-03       Impact factor: 91.245

5.  Incidence of hepatitis B in the penitentiary of New Mexico.

Authors:  H F Hull; L H Lyons; J M Mann; S C Hadler; R Steece; M R Skeels
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

6.  HIV infection among women entering the New York State correctional system.

Authors:  P F Smith; J Mikl; B I Truman; L Lessner; J S Lehman; R W Stevens; E A Lord; R K Broaddus; D L Morse
Journal:  Am J Public Health       Date:  1991-05       Impact factor: 9.308

7.  Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994.

Authors:  G M McQuillan; P J Coleman; D Kruszon-Moran; L A Moyer; S B Lambert; H S Margolis
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

8.  Hepatitis B vaccination of inmates in correctional facilities--Texas, 2000-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-08-06       Impact factor: 17.586

9.  Seroepidemiology of hepatitis B in Tennessee prisoners.

Authors:  M D Decker; W K Vaughn; J S Brodie; R H Hutcheson; W Schaffner
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

10.  Hepatitis B in Wisconsin male prisoners: considerations for serologic screening and vaccination.

Authors:  R F Anda; S B Perlman; D J D'Alessio; J P Davis; V N Dodson
Journal:  Am J Public Health       Date:  1985-10       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.